Supplements for glioblastoma side effects

Bottom line Verified Answer #1

December 2026 is still in the future. The current time supplied is August 14, 2026 UTC, so this answer can evaluate research available only through August 13–14, 2026, not studies that may appear between now and December 31, 2026. Verified Answer #1

Using a strict definition of demonstrated clinical efficacy—a controlled, reproducible benefit in patients meeting the modern definition of Grade 4 glioblastoma and receiving contemporary radiotherapy plus temozolomide—no dietary supplement has yet met that standard for mitigating treatment side effects. Verified Answer #1

The current SNO/EANO consensus review similarly describes the role of diet and nutritional supplements in glioblastoma as unclear because very few well-conducted studies are available. (academic.oup.com) Verified Answer #1

There are, however, two supplements with direct positive human signals: Verified Answer #1

Boswellia serrata/boswellic-acid extract — the strongest, though still low-certainty, evidence; it may reduce treatment-associated cerebral edema on MRI. Verified Answer #1

Melatonin — one small, old randomized trial reported lower radiotherapy- or steroid-related toxicity, but the toxicity outcomes were poorly specified and the study predates temozolomide. Verified Answer #1

No supplement has demonstrated controlled efficacy specifically for temozolomide-associated nausea/vomiting, constipation, fatigue, lymphopenia, neutropenia, thrombocytopenia, or hepatotoxicity in Grade 4 glioblastoma. Verified Answer #1

Evidence summary Verified Answer #1

| Supplement | Clinical evidence in glioblastoma/brain-tumor patients | Side effect studied | Evidence judgment | |---|---|---|---| | Boswellia serrata | Randomized double-blind pilot trial of 44 irradiated malignant-brain-tumor patients, approximately 25% with glioblastoma; plus an uncontrolled 20-patient GBM chemoradiotherapy study | Cerebral edema; possible reduction in steroid requirement | Positive radiographic signal, but not definitive GBM-specific clinical efficacy | | Melatonin | Thirty-patient randomized GBM trial of radiotherapy alone versus radiotherapy plus 20 mg/day | Unspecified radiotherapy- and steroid-related toxicity | Preliminary historical signal only; not replicated in modern TMZ-treated GBM | | High-dose IV vitamin C/ascorbate | Small uncontrolled Phase I trial with RT/TMZ | Safety and adverse-event profile | Not proof of side-effect mitigation; pharmacologic IV treatment rather than ordinary supplementation | | THC:CBD cannabis oils | Active-comparator trial in recurrent/inoperable high-grade glioma | Sleep, functional well-being and quality of life | Possible symptomatic benefit, but no placebo group and no demonstrated reduction of RT/TMZ toxicity | | Salovum/antisecretory factor | Pilot safety studies and a small edema study | Peritumoral edema/steroid use | No significant edema benefit demonstrated | | Curcumin, probiotics, omega-3 fatty acids, vitamin D, selenium, resveratrol and similar products | Mainly laboratory, animal, safety or antitumor studies | Generally not tested as supportive treatment in controlled GBM trials | No demonstrated GBM-specific toxicity-mitigation efficacy | Verified Answer #1

Boswellia serrata: the most credible candidate, specifically for cerebral edema Verified Answer #1

Randomized evidence Verified Answer #1

Kirste and colleagues randomized 44 patients with primary or secondary malignant brain tumors undergoing brain radiotherapy to Boswellia serrata extract 4,200 mg/day or placebo. Verified Answer #1

Approximately 25% of the cohort had glioblastoma, while the remainder principally had brain metastases. Verified Answer #1

At completion of radiotherapy, a greater-than-75% reduction in MRI-measured edema occurred in 60% with Boswellia versus 26% with placebo—an absolute difference of 34 percentage points, corresponding to a nominal number needed to treat of about three for that radiographic endpoint. Verified Answer #1

The result was statistically significant, P = .023. (acsjournals.onlinelibrary.wiley.com) Verified Answer #1

Important limitations substantially weaken the conclusion: Verified Answer #1

Results were reported for the mixed brain-tumor cohort, not separately for the roughly 11 glioblastoma patients. Verified Answer #1

The groups no longer differed four weeks after Boswellia/placebo was discontinued. Verified Answer #1

Boswellia did not significantly improve quality of life, cognitive function or dexamethasone use. Verified Answer #1

Greater tumor shrinkage in the Boswellia group may have partly produced the edema reduction, so the trial could not cleanly distinguish an anti-edema effect from a tumor-response effect. Verified Answer #1

Six Boswellia recipients developed minor gastrointestinal discomfort/grade 1–2 diarrhea. (acsjournals.onlinelibrary.wiley.com) Verified Answer #1

Thus, this trial demonstrated short-term radiographic edema reduction, not a proven improvement in symptoms or functional status specifically among modern molecularly defined Grade 4 glioblastoma patients. Verified Answer #1

GBM-only chemoradiotherapy evidence Verified Answer #1

A later single-arm study enrolled 20 patients with newly diagnosed GBM undergoing surgery followed by radiotherapy and temozolomide. Verified Answer #1

Patients received a lecithin-based Boswellia formulation, Monoselect AKBA, 4,500 mg/day, for up to 34 weeks. Verified Answer #1

The investigators reported increasing proportions of patients with stable or reduced edema and that many patients had stable or reduced dexamethasone doses or became dexamethasone-free. Verified Answer #1

Quality of life and psychological measures were maintained. (minervamedica.it) Verified Answer #1

Because this study had no placebo or contemporaneous control group, it cannot determine whether Boswellia caused those outcomes. Verified Answer #1

Edema can improve because of surgery, radiotherapy, temozolomide, tumor response, natural fluctuation or changing steroid doses. Verified Answer #1

The authors therefore appropriately concluded only that the formulation might have a beneficial effect. (minervamedica.it) Verified Answer #1

Boswellia conclusion Verified Answer #1

Boswellia is the only dietary supplement with a reasonably direct human efficacy signal for a specific GBM-treatment complication: cerebral edema during cranial radiotherapy/chemoradiotherapy. Nevertheless, the evidence is still low certainty, does not establish symptomatic or steroid-sparing efficacy, and has not resulted in Boswellia becoming standard supportive care. Verified Answer #1

The U.S. Verified Answer #1

National Center for Complementary and Integrative Health likewise describes the brain-edema findings as encouraging but concludes that there is insufficient high-quality evidence to establish Boswellia’s usefulness. (nccih.nih.gov) Verified Answer #1

Trial doses of 4.2–4.5 g/day were formulation-specific and should not be assumed equivalent to the same number of milligrams from an arbitrary commercial product. Verified Answer #1

Melatonin: an unconfirmed historical signal Verified Answer #1

A 1996 randomized trial assigned 30 glioblastoma patients to radiotherapy alone—60 Gy—or radiotherapy plus oral melatonin 20 mg/day, continued until progression. Verified Answer #1

The study reported both better one-year survival, 6 of 14 versus 1 of 16, and lower radiotherapy- or steroid-related toxicity among melatonin recipients. (pubmed.ncbi.nlm.nih.gov) Verified Answer #1

That result cannot support routine use today because: Verified Answer #1

The trial included only 30 patients. Verified Answer #1

The publication’s abstract did not clearly enumerate the particular toxicities, event counts, severity grades or toxicity assessment procedures. Verified Answer #1

Toxicity mitigation was not the clearly defined primary endpoint. Verified Answer #1

It was conducted before concomitant and adjuvant temozolomide became standard, so it provides no evidence that melatonin reduces temozolomide toxicity. Verified Answer #1

The finding has not been robustly replicated in a modern, adequately powered GBM trial. Verified Answer #1

Its pathological definition of “glioblastoma” predates current molecular classification and may not map exactly to present-day WHO-defined glioblastoma. Verified Answer #1

Current Grade 4 glioma guidance incorporates the revised molecular classification. (astro.org) Verified Answer #1

Therefore, melatonin should be classified as very-low-certainty preliminary evidence, not a supplement with established toxicity-mitigating efficacy. Verified Answer #1

Why other frequently proposed supplements do not qualify Verified Answer #1

Pharmacologic intravenous vitamin C Verified Answer #1

A first-in-human Phase I study combined high-dose IV pharmacologic ascorbate with radiotherapy and temozolomide in newly diagnosed GBM. Verified Answer #1

Eleven patients were evaluable; no dose-limiting toxicity occurred, and the overall toxicity profile was described as similar to historical controls. Verified Answer #1

However, the study lacked a randomized control arm and was designed primarily to determine safety and dosing, not to establish side-effect reduction. Verified Answer #1

Dry mouth and chills were attributed to the ascorbate infusions, and one patient developed grade 3 hypokalemia attributed to treatment. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

Consequently, IV ascorbate is investigational pharmacologic therapy, not a demonstrated dietary-supplement remedy for chemoradiotherapy side effects. “No additional toxicity” or “favorable compared with historical experience” is not equivalent to evidence that it mitigates toxicity. Verified Answer #1

Medicinal cannabis oils Verified Answer #1

A randomized study compared two active THC:CBD ratios in recurrent or inoperable high-grade glioma and reported improvement from baseline in sleep, functional well-being and quality of life. Verified Answer #1

But it lacked a placebo/no-cannabis arm, included high-grade gliomas rather than a uniform newly diagnosed Grade 4 GBM chemoradiotherapy population, and did not demonstrate that cannabis reduced adverse effects caused by radiotherapy or temozolomide. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

Cannabis may have a role in individualized symptom management, but this study does not establish it as a dietary supplement that mitigates GBM-treatment toxicity. Verified Answer #1

Salovum/antisecretory factor Verified Answer #1

An eight-patient pilot found that Salovum, an antisecretory-factor-enriched egg-yolk medical food, was feasible and generally safe during GBM radiochemotherapy, although nausea and appetite loss caused one treatment-related withdrawal. Verified Answer #1

Its apparent steroid-sparing signal was uncontrolled. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

A subsequent study of 15 Salovum-treated patients and 10 controls found no significant difference in edema-volume reduction—mean reductions of 7.1 versus 11.3 cm³, P = .61. Verified Answer #1

It therefore has not demonstrated anti-edema efficacy. (pmc.ncbi.nlm.nih.gov) Verified Answer #1

Curcumin and probiotics Verified Answer #1

A 2026 Phase I/II study of liposomal curcumin combined with standard chemoradiation investigated safety and exploratory tumor control, not mitigation of treatment side effects; curcumin-related grade 3 or higher toxicities occurred in approximately 16% of evaluated patients. (ascopubs.org) Verified Answer #1

The frequently cited finding that Lactobacillus rhamnosus GG reduces temozolomide-associated intestinal injury came from a glioblastoma mouse model, not patients. Verified Answer #1

It cannot support clinical efficacy in humans. (pubmed.ncbi.nlm.nih.gov) Verified Answer #1

Important correction to several previous answers: temozolomide is not highly CYP450-dependent Verified Answer #1

Several earlier answers asserted that temozolomide depends heavily on hepatic cytochrome P450 metabolism and that supplements could therefore markedly alter its clearance through CYP induction or inhibition. Verified Answer #1

That mechanism is substantially incorrect. Verified Answer #1

The FDA prescribing information states that temozolomide undergoes rapid nonenzymatic conversion and spontaneous hydrolysis at physiological pH to MTIC; cytochrome P450 enzymes play only a minor role in temozolomide and MTIC metabolism. (accessdata.fda.gov) Verified Answer #1

This does not mean that every supplement is safe with GBM therapy—products may affect bleeding, sedation, gastrointestinal tolerance, liver function, other medications or treatment adherence—but CYP-mediated alteration of temozolomide clearance should not be presented as the principal universal interaction mechanism. Verified Answer #1

Final answer Verified Answer #1

Established, replicated supplement for chemotherapy side effects in contemporary Grade 4 glioblastoma: None. Verified Answer #1

Established supplement for patient-centered radiation toxicity outcomes: None. Verified Answer #1

Best-supported positive candidate: Boswellia serrata/boswellic acids, specifically for short-term MRI-measured cerebral edema during brain radiotherapy or radiochemotherapy; evidence remains low certainty and does not prove symptomatic or steroid-sparing benefit. Verified Answer #1

Second, substantially weaker candidate: Melatonin 20 mg/day, based on one small 1996 trial reporting lower unspecified radiotherapy/steroid toxicity; unreplicated, pre-temozolomide and not sufficient for current clinical recommendation. Verified Answer #1

IV ascorbate, cannabis oils, Salovum, curcumin, probiotics, omega-3, vitamin D, selenium, resveratrol and similar products: no controlled Grade 4 GBM evidence establishes mitigation of contemporary chemoradiotherapy side effects. Verified Answer #1

A patient should therefore not replace dexamethasone, antiemetics, blood-count monitoring, infection prophylaxis or other prescribed supportive care with a supplement. Verified Answer #1

Boswellia or melatonin should be considered, if at all, only after review by the treating neuro-oncologist and an oncology pharmacist, because the studied formulations and doses are not interchangeable with arbitrary retail products. Verified Answer #1

Key primary references Verified Answer #1

Kirste, S., Treier, M., Wehrle, S. Verified Answer #1

J., Becker, G., Abdel-Tawab, M., Gerbeth, K., Hug, M. Verified Answer #1

J., Lubrich, B., Grosu, A.-L., & Momm, F. (2011). Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer, 117, 3788–3795. doi:10.1002/cncr.25945. (acsjournals.onlinelibrary.wiley.com) Verified Answer #1

Di Pierro, F., Simonetti, G., Petruzzi, A., Bertuccioli, A., Botta, L., Bruzzone, M. Verified Answer #1

G., Cuccarini, V., Fariselli, L., & Lamperti, E. (2019). A novel lecithin-based delivery form of boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: A longitudinal pilot experience. Journal of Neurosurgical Sciences, 63(3), 286–291. doi:10.23736/S0390-5616.19.04662-9. (minervamedica.it) Verified Answer #1

Lissoni, P., Meregalli, S., Nosetto, L., Barni, S., Tancini, G., Fossati, V., & Maestroni, G. (1996). Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology, 53(1), 43–46. doi:10.1159/000227533. (pubmed.ncbi.nlm.nih.gov) Verified Answer #1

Sources: [1] Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions | Neuro-Oncology | Oxford Academic [2] Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors [3] Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors - Kirste - 2011 - Cancer - Wiley Online Library [4] A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience - Journal of Neurosurgical Sciences 2019 June;63(3):286-91 - Minerva Medica - Journals [5] Boswellia: Usefulness and Safety | NCCIH [6] Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone - PubMed [7] ASTRO updates guideline on radiation therapy for high-grade diffuse glioma - American Society for Radiation Oncology (ASTRO) [8] First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma - PMC [9] A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas - PMC [10] Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma - PMC [11] Antisecretory factor for treatment of peritumoral edema in glioblastoma patients - PMC [12] Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas. | Journal of Clinical Oncology [13] Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4-NFκB Signaling Pathway - PubMed [14] TEMODAR (temozolomide) Highlights of Prescribing Information Verified Answer #1